Short-term clinical and serological follow-up with conventional and conformational anti-desmoglein antibodies in treatment-naïve and previously treated patients with pemphigus vulgaris after receiving rituximab

• Egile Nagusiak: Hoorieh Alaeen, MD (Egilea), Roja Toosi, MD, MPH (Egilea), Hamidreza Mahmoudi, MD (Egilea), Kamran Balighi, MD (Egilea), Soheil Tavakolpour, MS (Egilea), Amir Teimoupour, PhD (Egilea), Maryam Daneshpazhooh, MD (Egilea)
• Formatua: Liburua
• Argitaratua: Wolters Kluwer, 2019-12-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Background: Pemphigus vulgaris (PV) is a blistering, life-threatening autoimmune disease. Ethylenediaminetetraacetic acid (EDTA)-treated desmoglein (Dsg) enzyme-linked immunosorbent assay (ELISA) has recently been suggested to detect nonpathogenic antibodies. Rituximab (RTX) is now considered a firs...